Filtered By:
Management: National Institutes of Health (NIH)
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 769 results found since Jan 2013.
Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study
Even though it can make infections worse, it also may be able to keep the immune system from overreacting.
Source: NYT Health - April 14, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: your-feed-science Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Rheumatoid Arthritis Eli Lilly and Company Clinical Trials Remdesivir (Drug) National Institute of Allergy and Infectious Diseases National Institutes of Health Source Type: news
Despite Qualms, Arthritis Drug Is to Be Tested in Coronavirus Study
Even though it can make infections worse, it also may be able to keep the immune system from overreacting.
Source: NYT Health - April 14, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: your-feed-science Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Rheumatoid Arthritis Eli Lilly and Company Clinical Trials Remdesivir (Drug) National Institute of Allergy and Infectious Diseases National Institutes of Health Source Type: news
Temple Researchers awarded $1.98 million from NIAID to investigate T-cell activation
(Temple University Health System) Thanks to a new $1.98M grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID), scientists at the Lewis Katz School of Medicine at Temple University are poised to make major headway into the study of immunological synapse formation.
Source: EurekAlert! - Biology - April 14, 2020 Category: Biology Source Type: news
UCLA is part of NIH-sponsored clinical trial for possible COVID-19 therapies
UCLA Health is one of 75 sites around the globe participating in a clinical trial sponsored by the National Institutes of Health to test the effectiveness of a candidate antiviral drug against COVID-19.The drug, called remdesivir, was originally developed as a treatment for Ebola. Although it was found to be safe, it was not effective in treating patients with the disease. In laboratory tests, however, it appears to work against the SARS-CoV-2 virus that causes COVID-19, which has raised hope that it may be effective against the coronavirus that has swept the globe, sickening and killing thousands.The clinical trial wa...
Source: UCLA Newsroom: Health Sciences - April 3, 2020 Category: Universities & Medical Training Source Type: news
Trial for Potential Coronavirus Treatment is Underway at Montefiore and Einstein
April 3, 2020—(BRONX, NY)—Montefiore Health System andAlbert Einstein College of Medicine has joined a clinical trial to evaluate the experimental drug remdesivir to treat people who are hospitalized with severe COVID-19 infection. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial. This treatment has the potential to help people who have serious lung complications as a result of COVID-19. Recruitment for the trial began in March and is still underway.
Source: Einstein News - April 3, 2020 Category: Universities & Medical Training Source Type: news
As the First Coronavirus Vaccine Human Trials Begin, Manufacturer Is Already Preparing to Scale Production to Millions
Last week, the first volunteers in a study of an experimental COVID-19 vaccine received their first doses, and the vaccine’s developer, Moderna Therapeutics, is already thinking ahead. Although testing on the vaccine will take at least a year to complete, the work could provide valuable information about how the immune system can fight coronaviruses and could give scientists a head start if any new outbreaks of the virus were to occur.
Non-essential staff at Moderna Therapeutics’ manufacturing facility, in Norwood, Mass., including president Dr. Stephen Hoge, are working from home as recommended by public healt...
Source: TIME: Health - March 23, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Africa: Human Trial of Investigational COVID-19 Vaccine Begins
[NIH] Seattle -A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID's Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years
Source: AllAfrica News: Health and Medicine - March 18, 2020 Category: African Health Source Type: news
New AIBS Report on Biological Sciences in the President ' s FY 2021 Budget
A new report from the American Institute of Biological Sciences (AIBS) provides an analysis of the President’s fiscal year (FY) 2021 budget request for biological sciences research and education.
The report provides an overview and analysis of the budget request for several federal agencies and programs, including the National Science Foundation, National Institutes of Health (NIH), National Institute of Standards and Technology, United States Geological Survey, Department of Energy Office of Science, National Oceanic and Atmospheric Administration, and Environmental Protection Agency, among others.
Most federal s...
Source: Public Policy Reports - March 17, 2020 Category: Biology Authors: AIBS Source Type: news
New coronavirus stable for hours on surfaces
(NIH/National Institute of Allergy and Infectious Diseases) The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study from National Institutes of Health, CDC, UCLA and Princeton University scientists in NEJM. They found that (SARS-CoV-2) was detectable in aerosols for up to three hours, up to four hours on copper, up to 24 hours on cardboard and up to two to three days on plastic and stainless steel.
Source: EurekAlert! - Infectious and Emerging Diseases - March 17, 2020 Category: Infectious Diseases Source Type: news
New Tests Enter the Scene as COVID-19 Rages On
Tests for the coronavirus (COVID-19) continue to roll in as the U.S. faces a public health crisis. Thermo Fisher Scientific and Mayo Clinic are the latest with diagnostic contributions.
Waltham, MA-based Thermo Fisher is the second company to be granted an Emergency Use Authorization for a commercially developed COVID-19 test. MD+DI reported Roche received this designation late last week too for the cobas SARA-COV-2 test.
In a press release, Thermo Fisher said the authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab...
Source: MDDI - March 16, 2020 Category: Medical Devices Authors: Omar Ford Tags: IVD Regulatory and Compliance Source Type: news
How the U.S. plans to correct the "failing" coronavirus testing system
Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, said Thursday the United States' coronavirus testing system was "failing." He joins "CBS This Morning" to discuss what the country is doing to correct the system and get more people tested.
Source: Health News: CBSNews.com - March 13, 2020 Category: Consumer Health News Source Type: news
China ’s Draconian Lockdown Is Getting Credit for Slowing Coronavirus. Would It Work Anywhere Else?
As COVID-19 spread rapidly across China, authorities took an aggressive stance to fight the coronavirus. They were slow to respond to the outbreak—at first suppressing information and denying that it could spread between humans even as it did just that. But, as case numbers skyrocketed, Beijing went to extraordinary lengths to fight the virus, identified at COVID-19, in a campaign Chinese President Xi Jinping has described as a “people’s war.”
The most dramatic, and controversial, of the measures was the lockdown of of tens of millions of people in what is believed to be the largest quasi-quarantin...
Source: TIME: Health - March 13, 2020 Category: Consumer Health News Authors: Amy Gunia Tags: Uncategorized COVID-19 overnight Source Type: news
Not His First Epidemic: Dr. Anthony Fauci Sticks to the Facts
Where politicians fumble and other government health officials step back, he steps up to explain.
Source: NYT - March 9, 2020 Category: American Health Authors: Denise Grady Tags: Coronavirus (2019-nCoV) United States Politics and Government Science and Technology Epidemics Research National Institute of Allergy and Infectious Diseases National Institutes of Health Fauci, Anthony S your-feed-healthcare Source Type: news
COVID-19 Vaccine Shipped, and Drug Trials Start
Moderna Therapeutics, a biotech company based in Cambridge, Mass., has shipped the first batches of its COVID-19 vaccine. The vaccine was created just 42 days after the genetic sequence of the COVID_19 virus, called SARS-CoV-2, was released by Chinese researchers in mid-January. The first vials were sent to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in Bethesda, MD, which will ready the vaccine for human testing as early as April.
NIH scientists also began testing an antiviral drug called remdesivir that had been developed for Ebola, on a patient infec...
Source: TIME: Health - February 25, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Cambridge biotech delivers coronavirus vaccine
Government researchers are set to begin testing the first potential coronavirus vaccine, thanks to an emerging Cambridge biotech.
Moderna Inc. (Nasdaq: MRNA) reported after markets closed Monday it has delivered the first batch of its vaccine for COVID-19 over to a branch of the National Institutes of Health for clinical testing. The NIH's allergy and infectious disease institute will lead the next leg of development thr ough a collaboration between it and Moderna.
The Cambridge startup is…
Source: bizjournals.com Health Care:Biotechnology headlines - February 25, 2020 Category: Biotechnology Authors: Allison DeAngelis Source Type: news
